New shot could ease heart failure in obese patients
NCT ID NCT06391710
First seen Nov 25, 2025 · Last updated May 22, 2026 · Updated 23 times
Summary
This study tests an investigational injection called HRS9531 in 200 obese adults with a type of heart failure (preserved ejection fraction). Participants receive either the drug or a placebo weekly for 52 weeks. The goal is to see if the drug improves heart failure symptoms and helps with weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, 100020, China
Conditions
Explore the condition pages connected to this study.